• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome.

作者信息

Wetzels Jack F M, van de Kar Nicole C A J

机构信息

Radbound University Medical Center, Nijmegen, the Netherlands.

出版信息

Am J Kidney Dis. 2015 Feb;65(2):342. doi: 10.1053/j.ajkd.2014.04.039.

DOI:10.1053/j.ajkd.2014.04.039
PMID:25616634
Abstract
摘要

相似文献

1
Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome.依库珠单抗维持治疗非典型溶血性尿毒症综合征的停药情况。
Am J Kidney Dis. 2015 Feb;65(2):342. doi: 10.1053/j.ajkd.2014.04.039.
2
In reply to 'discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome'.关于“终止依库珠单抗维持治疗非典型溶血尿毒症综合征”的回复
Am J Kidney Dis. 2015 Feb;65(2):342-3. doi: 10.1053/j.ajkd.2014.05.028.
3
Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update.非典型溶血性尿毒症综合征中依库珠单抗治疗的停药：最新进展
Am J Kidney Dis. 2015 Jul;66(1):172-3. doi: 10.1053/j.ajkd.2015.04.010.
4
Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.停止依库珠单抗维持治疗非典型溶血尿毒综合征：10 例报告。
Am J Kidney Dis. 2014 Oct;64(4):633-7. doi: 10.1053/j.ajkd.2014.01.434. Epub 2014 Mar 19.
5
Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab.停用依库珠单抗后亚临床非典型溶血尿毒综合征复发。
Nephrology (Carlton). 2017 Feb;22 Suppl 1:4-6. doi: 10.1111/nep.12931.
6
Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH.因CFH基因突变导致非典型溶血性尿毒症综合征患者停用依库珠单抗。
Am J Kidney Dis. 2016 Mar;67(3):532-3. doi: 10.1053/j.ajkd.2015.11.009. Epub 2015 Dec 23.
7
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.依库珠单抗的治疗药物监测：个体化给药方案的理论依据。
MAbs. 2015;7(6):1205-11. doi: 10.1080/19420862.2015.1086049. Epub 2015 Sep 4.
8
Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.非典型溶血性尿毒症综合征：病例报告的荟萃分析证实基因突变的患病率及治疗方案的转变
Ther Apher Dial. 2018 Apr;22(2):178-188. doi: 10.1111/1744-9987.12641. Epub 2017 Dec 17.
9
Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.终端补体抑制剂依库珠单抗治疗成人非典型溶血尿毒综合征：一项单臂、开放标签试验。
Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.
10
Eculizumab for aHUS post-transplantation: when and how to stop a good thing.依库珠单抗用于移植后非典型溶血尿毒症综合征：何时以及如何停用有益药物。
Transpl Int. 2015 Aug;28(8):1000-1. doi: 10.1111/tri.12566. Epub 2015 Mar 31.

引用本文的文献

1
Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report.终末补体抑制剂依库珠单抗在一名14个月大中国儿科患者非典型溶血性尿毒症综合征治疗中的应用：一例报告
Front Pediatr. 2024 Jul 31;12:1404725. doi: 10.3389/fped.2024.1404725. eCollection 2024.
2
Kidney diseases.肾脏疾病。
Immunol Rev. 2023 Jan;313(1):239-261. doi: 10.1111/imr.13167. Epub 2022 Nov 12.
3
Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy.
补体系统作为造血干细胞移植相关血栓性微血管病的新靶点
Pharmaceuticals (Basel). 2022 Jul 9;15(7):845. doi: 10.3390/ph15070845.
4
The Rational Use of Complement Inhibitors in Kidney Diseases.补体抑制剂在肾脏疾病中的合理应用
Kidney Int Rep. 2022 Mar 4;7(6):1165-1178. doi: 10.1016/j.ekir.2022.02.021. eCollection 2022 Jun.
5
Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation.补体基因变异对依库珠单抗停药后补体介导的血栓性微血管病复发的影响。
Blood Adv. 2023 Feb 14;7(3):340-350. doi: 10.1182/bloodadvances.2021006416.
6
Ravulizumab: Characterization and quantitation of a new C5 inhibitor using isotype specific affinity purification and high-resolution mass spectrometry.瑞武利单抗：使用同型特异性亲和纯化和高分辨率质谱法对新型C5抑制剂进行表征和定量分析。
J Mass Spectrom Adv Clin Lab. 2021 Aug 12;21:10-18. doi: 10.1016/j.jmsacl.2021.08.002. eCollection 2021 Aug.
7
Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality.携带补体调节基因异常患者家庭成员中不典型溶血尿毒综合征的风险
Kidney Int Rep. 2021 Mar 25;6(6):1614-1621. doi: 10.1016/j.ekir.2021.03.885. eCollection 2021 Jun.
8
Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.血栓性微血管病在 aHUS 及其他疾病中的作用：补体遗传学的临床线索。
Nat Rev Nephrol. 2021 Aug;17(8):543-553. doi: 10.1038/s41581-021-00424-4. Epub 2021 May 5.
9
Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome.一项针对非典型溶血性尿毒症综合征中补体抑制治疗停药的临床医生指导方案的结果。
Blood Adv. 2021 Mar 9;5(5):1504-1512. doi: 10.1182/bloodadvances.2020003175.
10
Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.抗磷脂综合征：补体激活、补体基因突变与治疗意义。
J Thromb Haemost. 2021 Mar;19(3):607-616. doi: 10.1111/jth.15082. Epub 2021 Feb 10.